Allena Pharmaceuticals Inc

Allena Pharmaceuticals — Investor Presentation (October 2018)

25 slides from Allena Pharmaceuticals's investor presentation, Oct 2, 2018

  1. Slide 1: Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders

    Bringing First-in-Class Oral Enzyme Therapeutics to Patients with Rare and Severe Metabolic and Kidney Disorders October 2018 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Allena Pharmaceuticals, Inc. These slides contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are

  3. Slide 3: Investment Highlights

    Investment Highlights Significant Unmet Need in Oxalate and Urate Disorders Late-Stage Development Candidate: Reloxaliase Pioneering Expertise in Oral Enzyme Therapeutics Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and E

  4. Slide 4: Allena's Pipeline: First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders

    Product Indication Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Next Milestone Commercial Rights Reloxaliase Enteric hyperoxaluria 2H ’18: Initiate URIROX-2 Worldwide Systemic oxalosis* 2H ’18: Interim data Worldwide Primary hyperoxaluria* (Orphan Designation) 2H ’18: Interim data Worldwide Pediat

  5. Slide 5: Hyperoxaluria is Characterized by Markedly Elevated Urinary Oxalate Levels

    Hyperoxaluria is Characterized by Markedly Elevated Urinary Oxalate Levels Source: Illustration adapted from Coe, Fred. “Control of Urine Oxalate Excretion.” Kidneystones.uchicago.edu. University of Chicago, kidneystones.uchicago.edu/control-of-urine-oxalate-excretion . March 2017. Fecal Excretion G

  6. Slide 6: First-in-Class Therapeutic Strategy in Enzyme Therapeutics

    First-in-Class Therapeutic Strategy Expertise and Proprietary Technological Approach in Enzyme Therapeutics Enables First-in-Class Therapeutic Strategy for Oxalate and Urate Disorders Reloxaliase Recombinant Protein Oral, non-absorbed, highly specific Optimized Highly Active Form of the Enzyme for G

  7. Slide 7: No FDA approved pharmacological therapies to treat any form of hyperoxaluria

    There are no FDA approved pharmacological therapies to treat any form of hyperoxaluria Enteric Hyperoxaluria (EH) Urinary Oxalate (UOx) Study 713 Patient Examples Whipple (Pancreatic Insufficiency): 14 stones in last 5 years (16 stones visible by CT) Celiac disease: 3 stones in last 2 years ( 4 ston

  8. Slide 8: Reloxaliase Initially Targets Enteric Hyperoxaluria Patients with Underlying Malabsorptive GI Diseases

    Reloxaliase Initially Targets Enteric Hyperoxaluria Patients with Underlying Malabsorptive GI Diseases and Kidney Stones 1 Truvan Health Analytics, part of the IBM Watson Health business longitudinal Claims Analysis, August 2017. Analysis tracked patients for whom an enteric disease diagnosis or pro

  9. Slide 9: Risk of Renal Complications Rises with Higher Urinary Oxalate Levels

    Risk of Renal Complications Rises with Higher Urinary Oxalate Levels: Reduction of UOx Improves Renal Outcomes Illustrative Diagram Sources: Robertson and Hughes, Scanning Microsc. 1993; Keddis Curr Opin Nephrol Hypertens. 2013; Robertson and Peacock, Nephron. 1980; Milliner, Kidney Int. 2006; Curha

  10. Slide 10: The Patient Journey for Severe Hyperoxaluria Patients

    The Patient Journey for Severe Hyperoxaluria Patients can Include Complex Specialty Care with Progressive Disease Recurrent Kidney Stones Stone Clinic Kidney Stone Disease Management Nephrologist/Urologist Metabolic Management Complex Specialty Care Monitoring Kidney Function Nephrologist Renal Dama

  11. Slide 11: Reloxaliase for the Treatment of Hyperoxaluria

    Reloxaliase for the Treatment of Hyperoxaluria

  12. Slide 12: Clinical and Regulatory Progression of Reloxaliase

    Clinical and Regulatory Progression of Reloxaliase Pre clinical Ph 1 Healthy Volunteers Ph 2 Open Label Ph 2 Randomized Controlled Ph 3 Randomized Controlled ✓ ✓ ✓ ✓ Initiate 1Q 2018 and 2H 2018 Progressive Increase in Enzyme Activity Porcine Rhubarb Model Presented at AUA 2016 Porcine Western Diet

  13. Slide 13: Phase 3 Program Incorporates Key Learnings from Phase 2

    Phase 3 Program Incorporates Key Learnings from Phase 2 Phase 3 Phase 2 Program Identified Proposed Phase 3 Patient Population Enteric population demonstrated consistent, superior, clinically and statistically significant response Identified Proposed Pivotal Endpoint Percent change from baseline to

  14. Slide 14: Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population

    Study 713: Substantially Greater Reloxaliase Treatment Response in Enteric Population *Beyond the primary endpoint analysis, all P-values are descriptive. Enteric Reloxaliase Enteric Placebo Change in TWA Urinary Oxalate (mg/24h) Baseline Urinary Oxalate (mg/24h) Change in TWA UOx Excretion vs Basel

  15. Slide 15: Reloxaliase Generally Well-Tolerated in Clinical Trials to Date

    Reloxaliase Generally Well-Tolerated in Clinical Trials to Date 11,500 u/meal, 3,000 u/meal, and 7,500 u/meal. 2TEAE = Treatment emergent adverse events are defined as AEs with onset at the time of or following the first dose of treatment with study drug through 7 days after their last dose of study

  16. Slide 16: Reloxaliase: Proposed Pivotal Phase 3 Program in Enteric Hyperoxaluria

    1H 2017 2H 2017 1H 2018 2H 2018 1H 2019 2H 2019 1H 2020 2H 2020 1H 2021 Reloxaliase: Proposed Pivotal Phase 3 Program in Enteric Hyperoxaluria Proposed Phase 3 Program – in Discussions with the FDA, URIROX-1 Enrolling Patient Population: EH subjects with severe Hyperoxaluria (>50mg/24h), normal to m

  17. Slide 17: URIROX-1: Safety and Efficacy of Reloxaliase in Enteric Hyperoxaluria

    URIROX-1: Evaluate the Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria Key Features: Tailored dose regimen: dose with each meal/snack 3-5x per day to maximize degradation of oxalate ingested or secreted EP:Percent change from baseline in 24-h UOx excretion averaged during w

  18. Slide 18: Regulatory Status Overview

    Regulatory Status Overview: Hyperoxaluria is a High Unmet Need with No Approved Therapeutic Regulatory Challenge Opportunities Enteric Hyperoxaluria is a rare disease with a high burden of kidney stones and kidney damage High unmet need due to inadequate existing therapies With no approved drugs: No

  19. Slide 19: Reloxaliase Additional Indications

    Reloxaliase Additional Indications

  20. Slide 20: Elevated Plasma Oxalate Increases Risk for CaOx Crystal Deposition

    Elevated Plasma Oxalate Increases Risk for CaOx Crystal Deposition in the Kidney and Other Organ Systems Time and progression of disease Plasma Oxalate Level CKD 1 CKD 2 CKD 3 CKD 4 ESRD 0 15 30 45 2-5 µmol/L Normal range Systemic Oxalosis Dialysis Hyperoxalemia Study Population: Enteric Hyperoxalur

  21. Slide 21: Reloxaliase Potential to Reduce Oxalate Burden in Primary and Enteric Hyperoxaluria with Advanced CKD

    Reloxaliase has the Potential to Reduce Oxalate Burden in Patients with Primary Hyperoxaluria and Enteric Hyperoxaluria with Advanced CKD Sources: Grujic et al, Am. J Nephrol 2009; 29: 86-93 and company data *Pigs not colonized with oxalobacter formigenes. Degraded Oxalate in the GI Tract and Reduce

  22. Slide 22: Study 206: Reloxaliase in Primary or Enteric Hyperoxaluria and Advanced CKD

    Screening and Baseline 28 d Follow up 4 Weeks Study 206: Reloxaliase Treatment of Adult and Pediatric Patients with Primary or Enteric Hyperoxaluria and Advanced CKD ('Basket' Study) Primary Hyperoxaluria (PH) Enteric Hyperoxaluria (EH) Urinary Oxalate (UOx) Plasma Oxalate (POx) Regulatory: Reloxali

  23. Slide 23: ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD

    ALLN-346: Significant Opportunity in Gout Patients with Moderate-to-Severe CKD The Gout Market is Incompletely Served by Existing Therapies ~375,000 gout patients with moderate to severe CKD who have uncontrolled gout on urate lowering therapy (ULT) Gout patients with renal impairment are not well m

  24. Slide 24: Clinical and Regulatory Milestones

    Clinical and Regulatory Milestones YEAR TARGET MILESTONE STATUS (October 2018) 2017 4Q17 Initiate ALLN-346 Animal Studies ü 2018 1Q18 Initiate Study 301 ü 1Q18 Initiate Study 206, Phase 2 Study in PH and EH with Hyperoxalemia ü 2H18 Initiate Study 302 On Track 2H18 Study 206 Interim Data On Track 20

  25. Slide 25: Investment Highlights

    Investment Highlights Significant Unmet Need in Oxalate and Urate Disorders Late-Stage Development Candidate: Reloxaliase Pioneering Expertise in Oral Enzyme Therapeutics Focused on rare and severe metabolic disorders that can cause kidney stones, damage the kidney, and potentially lead to CKD and E

Allena Pharmaceuticals — Investor Presentation (October 2018) on 6ix